News about "Cancer Medicines Pathfinder"

EMA Recommends Rasonque's Authorisation for Metastatic Pancreatic Cancer

EMA Recommends Rasonque's Authorisation for Metastatic Pancreatic Cancer

EMA recommends authorisation of Rasonque for metastatic pancreatic cancer following a phased data review under its Cancer Medicines Pathfinder project.

Cancer Medicines Pathfinder | 19/10/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members